The glutathione system in Parkinson’s disease and its progression

Geir Bjørklund; Massimiliano Peana; Michael Maes; Maryam Dadar; Beatrice Severin

doi:10.1016/j.neubiorev.2020.10.004

Related publications

Article2021

Functional Connectomics and Disease Progression in Drug‐Naïve Parkinson's Disease Patients

Rosa De Micco, Federica Agosta, Silvia Basaia, Mattia Siciliano, Camilla Cividini, Gioacchino Tedeschi, Massimo Filippi, Alessandro Tessitore

Article2016

Highly specific changes in antioxidant levels and lipid peroxidation in Parkinson’s disease and its progression: Disease and staging biomarkers and new drug targets

Carine Coneglian de Farias, Michael Maes, Kamila Landucci Bonifácio, Chiara C. Bortolasci, André de Souza Nogueira, Francis F. Brinholi, Andressa Keiko Matsumoto, Matheus Amarante do Nascimento, Lúcio Baena de Melo, Suzana Lucy Nixdorf, Edson Lopes Lavado, Estefânia Gastaldello Moreira, Décio Sabbatini Barbosa

Article2021

The Role of White Matter Hyperintensities in Parkinson’s Disease Progression and Outcome (2710)

Pietro Giuseppe Scamarcia, Federica Agosta, Edoardo Gioele Spinelli, Tanya Stojkovic, Iva Stanković, Vladana Marković, Igor Petrović, Elka Stefanova, Vladimir Kostić, Massimo Filippi

Article2022

Stress system and related biomarkers in Parkinson's disease

Anastasia Bougea, Leonidas Stefanis, George Chrousos

Article2017

Secreted CLIC3 drives cancer progression through its glutathione-dependent oxidoreductase activity

Juan R. Hernández‐Fernaud, Elena Ruengeler, Andrea Casazza, Lisa J. Neilson, Ellie Pulleine, Alice Santi, Shehab Ismail, Sérgio Lilla, Sandeep Dhayade, Iain R. Macpherson, Iain A. McNeish, Darren Ennis, Hala M. Ali, Fernanda G. Kugeratski, Heba Al Khamici, Maartje van den Biggelaar, Peter V. E. van den Berghe, Catherine Cloix, Laura McDonald, David Millan, Aoisha Hoyle, Anna Kuchnio, Peter Carmeliet,